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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYGenetic engineering of human induced pluripotent stem cells (hiPSCs) via customized designer nucleases has been shown to be signif-
icantly more efficient than conventional gene targeting, but still typically depends on the introduction of additional genetic selection
elements. In our study, we demonstrate the efficient nonviral and selection-independent gene targeting in human pluripotent stem cells
(hPSCs). Our high efficiencies of up to 1.6%of gene-targeted hiPSCs, accompanied by a low background of randomly inserted transgenes,
eliminated the need for antibiotic or fluorescence-activated cell sorting selection, and allowed the use of short donor oligonucleotides for
footprintless gene editing. Gene-targeted hiPSC clones were established simply by direct PCR screening. This optimized approach allows
targeted transgene integration into safe harbor sites for more predictable and robust expression and enables the straightforward gener-
ation of disease-corrected, patient-derived iPSC lines for research purposes and, ultimately, for future clinical applications.INTRODUCTION
To date, it is extremely difficult to perform site-specific
transgenesis and gene targeting in patient-specific cells
due to the inability to sufficiently expand most primary
cell types or adult stem and progenitor cell lineages
in vitro. However, the availability of human induced
pluripotent stem cells (hiPSCs), with their far-reaching
potential for proliferation and differentiation, now offers
novel opportunities for biomedical research and ultimately
the development of tailored cellular therapies. The ability
to geneticallymodify pluripotent stem cells (PSCs) through
the introduction of reporter and selection genes or for the
overexpression of disease-related transgenes would further
broaden their usefulness for drug screening, disease
modeling, and cellular therapies. Moreover, the possibility
to genetically and functionally correct inherited gene de-
fects in patient-specific iPSCs may pave the way for novel
concepts of ex vivo gene therapy.
Clearly, conventional viral and nonviral gene transfer
technologies resulting in the random integration of the
introduced genetic elements and more or less unpredict-
able integration-site-dependent expression of the trans-
gene are not in accordance with the requirements ofStem Cecurrent biomedical research. It has also been shown in
animal experiments and clinical studies that random
integration and insertional mutagenesis can result in
the malignant transformation of stem cell transplants
(Hacein-Bey-Abina et al., 2003; Modlich et al., 2009; Stein
et al., 2010). It is therefore of the utmost importance to
develop more precise techniques that enable efficient
site-specific gene editing and safe long-term transgene
expression at well-defined genomic integration sites in
human PSCs (hPSCs) and especially iPSCs.
In murine embryonic stem cells (mESCs), gene targeting
through homologous recombination (HR) has been uti-
lized over the last 25 years to generate thousands of
knockout mice, which has led to major advances in our
basic understanding ofmammalian biology, gene function,
and disease mechanisms. Although the frequencies of HR
are rather low in classical approaches (104 to 106 in
mESCs) (Doetschman et al., 1988; Reid et al., 1991), such
techniques have so far represented the standard approach
for producing gene knockouts in mESCs and mice due to
the relative robustness of mESC culture and high trans-
fection rates in ESCs. Although two papers reported fre-
quencies of HR (1.5–4 3 106) in a range similar to that
seen in mESCs (Di Domenico et al., 2008; Zwaka andll Reports j Vol. 2 j 107–118 j January 14, 2014 j ª2014 The Authors 107
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ESCs (hESCs) is still considered to be more difficult and
less successful due to challenging culture characteristics
and lower transfection rates (Elliott et al., 2011; Goulburn
et al., 2011; Irion et al., 2007). Moreover, until recently,
the very low survival rates obtained after dissociation
prevented fluorescence-activated cell sorting (FACS) and
single-cell cloning. It is only since the invention of
the Rho-associated coiled-coil kinase (ROCK) inhibitor
Y-27632 that such techniques have become feasible for
hPSCs (Zweigerdt et al., 2011).
More recently, however, it has been demonstrated that
targeted induction of double-strand breaks (DSBs) by
employing tailored designer nucleases, such as zinc-finger
nucleases (ZFNs), transcription activator-like effector nu-
cleases (TALENs), and clustered regularly interspaced short
palindromic repeat (CRISPR) RNA-guided nucleases greatly
enhances HR (Fu et al., 2013; Mussolino and Cathomen,
2012; Rahman et al., 2011). ZFNs and TALENs consist of a
target-specific DNA-binding domain fused to an unspecific
nuclease domain, which induces a DSB upon activation. A
ZFN/TALEN-induced DSB can be repaired either by nonho-
mologous end joining (NHEJ) or by HR (Shrivastav et al.,
2008). Recent reports demonstrated that ZFNs and TALENs
allow for not only efficient gene inactivation throughNHEJ
but also enhanced HR-based gene targeting in hPSCs
(Hockemeyer et al., 2009, 2011; Soldner et al., 2011; Zou
et al., 2009). Remarkably, ZFN/TALEN-basedHRhas already
been applied for functional correction of genetic diseases
either by genotypic correction of the defective gene (Yusa
et al., 2011) or by insertion of the functional gene into a
safe harbor locus (Zou et al., 2011). The majority of gene-
targeting studies in hPSCs directly applied a transgene-
based antibiotic selection of targeted clones (Hockemeyer
et al., 2009, 2011; Sebastiano et al., 2011; Yusa et al.,
2011; Zou et al., 2011). Clearly, further improvements
in targeting efficiencies would not only minimize the
required screening procedures but would considerably
facilitate selection-independent targeting approaches in
PSCs, including footprintless restoration of wild-type
sequences in disease-specific iPSCs prior to their clinical
application.
Although in previous studies by Soldner et al. (2011) and
Ding et al. (2013), an initial FACS-based enrichment step of
TALEN-expressing cells prior to subsequent PCR-based
screening of this enriched cell population had to be
included, both groups provided initial evidence that the
footprintless correction of disease-specific mutations in
hPSCs without the need for an antibiotic selection is gener-
ally possible through the application of single-stranded
oligodeoxynucleotides (ssODNs).
In this study, we report on an efficient technique for
nonviral and selection-independent gene targeting in108 Stem Cell Reports j Vol. 2 j 107–118 j January 14, 2014 j ª2014 The AuthESCs and hiPSCs. For the development of our targeting
protocol, we first used an iPSC enhanced GFP (eGFP)
reporter system in which ZFNs were applied to disrupt
the eGFP open reading frame by NHEJ with an overall
efficiency of up to 4%, and to integrate a red fluorescent
protein into the eGFP locus by HR. Without any antibiotic
selection, we achieved HR-targeting efficiencies of up to
1.2% and could show that the ZFN-treated PSCs preserved
their pluripotency and chromosomal integrity. Finally, we
targeted the endogenous ‘‘safe harbor’’ locus AAVS1, which
is known for robust transgene expression in PSCs (Smith
et al., 2008). Here, by using ZFNs and TALENs, we obtained
targeting efficiencies comparable to those achieved with
our eGFP/RedStar reporter system for one hESC and two
hiPSC lines, and generated stable transgenic PSC lines by
FACS. Moreover, by applying TALENs together with short
ssODN donors without any preselection, we show that
the high targeting efficiencies obtained actually facilitate
direct PCR screening of correctly targeted clones. This
should enable footprintless gene correction and trans-
gene-independent isolation of mutation-corrected, dis-
ease-specific iPSC clones, and may ultimately lead to novel
concepts for iPSC-based ex vivo gene therapies.RESULTS
Efficient ZFN-Based Reporter Gene Inactivation in
Transgenic hiPSCs through NHEJ
To develop a reporter system for gene targeting in hPSCs,
we first established transgenic hiPSC clones stably express-
ing eGFP under control of the ubiquitous cytomegalovirus
early enhancer element and chicken beta-actin (CAG) pro-
moter as described in the Experimental Procedures. Opti-
mization of cell transfection included supplementation of
the ROCK inhibitor Y-27632 for improved survival after
single-cell dissociation (data not shown), the use of
feeder-free culture conditions, and a direct comparison of
two electroporation devices (Figure S1A available online).
Notably, we observed significantly higher transfection rates
after microporation using the Neon device as compared
with the Amaxa Nucleofection technology, which is
commonly considered to be the most efficient technique
for transfection of hPSCs. Under optimized conditions,
transfection rates of 72% ± 16% were observed in hPSCs
(Figure S1A). The application of these optimized transfec-
tion conditions followed by antibiotic selection led to the
isolation of two cell clones with single eGFP integration
(hCBiPS2eGFPC7 and hCBiPS2eGFPC16), an important
prerequisite for their use as a reporter cell line (Figures
S1B–S1E). To inactivate the eGFP reporter gene (Figure 1A),
we applied our protocol to transfect hCBiPS2eGFPC7 cells
with increasing amounts of eGFP-specific ZFN expressionhors
Figure 1. Efficient ZFN-Based Gene
Knockout in hPSCs
A hiPSC reporter line carrying a single eGFP
copy under control of the CAG promoter was
used.
(A) Scheme of eGFP knockout by ZFN-
mediated NHEJ. Gray arrows indicate pri-
mers used for cDNA sequencing.
(B) Flow-cytometric analysis of eGFP
disruption. Expression of eGFP-specific ZFNs
resulted in 3.3% eGFPneg iPSCs (continuous
line) at day 6 posttransfection as shown by
flow cytometry. The dotted line represents
the eGFP reporter cell line before trans-
fection. The gray histogram illustrates
hCBiPS2 cells without eGFP.
(C) Direct comparison of eGFP inactivation
through NHEJ between two hCBiPS2eGFP
reporter cell clones (C7 and C16). The
proportion of eGFPneg cells on day 6 after
transfection with eGFP-ZFN plasmids
(mean ± SEM of seven independent experi-
ments for direct comparison) is shown.
(D) Flow cytometry demonstrated a distinct
eGFPneg iPSC population only as of day 6
after transfection.
(E) ZFN-dose-dependent gene knockout. After transfection of hCBiPS2eGFPC7 cells with increasing amounts of ZFN-plasmid DNA, the
percentage of eGFPneg cells was determined by flow cytometry (depicted is the total amount of each ZFN plasmid; each point is a biological
replicate; mean ± SEM).
(F) Sequence analysis of eGFPneg iPSC clones. cDNA of all eGFPneg iPSC clones analyzed showed eGFP mutations surrounding the predicted
DSB. ZFN target sites are shown in capital letters. D, deletion of basepairs; +, insertion of base pairs.
See also Figure S1.
Stem Cell Reports
Footprintless Gene Targeting of Human iPSCsplasmids. Analysis of the percentage of eGFPneg cells at day
6 or 7 posttransfection via flow cytometry revealed a
distinct population of up to 4% eGFPneg cells (Figures 1B
and 1E). Comparative experiments with the second eGFP
reporter cell line hCBiPS2eGFPC16 revealed eGFP
knockout efficiencies of 2% (Figure 1C). Due to the high
stability of the eGFP protein, the distinct eGFPneg cell pop-
ulation emerged only at day 6 after transfection (Figure 1D).
Notably, the efficiency of eGFP inactivation was clearly
dependent on the amount of transfected ZFN encoding
plasmids (Figure 1E). To confirm the gene knockout, we
established eGFPneg hCBiPS2eGFPC7 cell clones via FACS
and prepared coding DNA. Sequencing of the eGFP open
reading frame of six randomly selected cell clones showed
a deletion of 5, 9, or 15 bp, or an insertion of 4 or 265 bp
overlapping with the ZFNs target sites compared with the
wild-type sequence (Figure 1F). These sequencing data
confirmed that all analyzed eGFPneg clones lost eGFP
expression due to ZFN-targeted inactivation through
the error-prone NHEJ; consequently, two clones showed
the same mutation and may have been derived from the
same NHEJ event.Stem CeEfficient HR-Mediated Gene Targeting in hiPSCs
Next, we utilized our reporter cell line to assess the effi-
ciency of HR-mediated gene targeting in hiPSCs. For this
purpose, an appropriate eGFP donor vector carrying a
2A-Redstarnuc-poly(A) expression cassette flanked by two
eGFP homology arms was constructed (Figure 2A). With
application of this vector, successful HR-mediated targeting
should result in the functional insertion of the RedStarnuc
cassette associated with transcriptional inactivation of
the eGFP gene. The utilization of a 2A sequence in our sys-
tem enables eGFP-locus-specific RedStarnuc expression and
should minimize the chance for undesired RedStarnuc
expression after random donor insertion.
Accordingly, hCBiPS2eGFPC7 cells were transfected with
different ratios of ZFN versus donor expression plasmids
and analyzed on day 3 and day 6 posttransfection. After
3 days, we obtained a distinct population of eGFPpos
RedStarpos cells, which turned into eGFPnegRedStarpos cells
after a further 3 days (Figure 2B). Flow-cytometric analysis
revealed up to 1.2% RedStarposeGFPneg hCBiPS2eGFPC7
cells and demonstrated a clear dependency on the
ZFN:donor ratio (Figure 2C). Similar experiments with thell Reports j Vol. 2 j 107–118 j January 14, 2014 j ª2014 The Authors 109
Figure 2. ZFN-Based Gene Targeting in hiPSCs
An iPSC reporter line carrying a single eGFP copy under control of the CAG promoter was used.
(A) Schematic illustration of the targeting strategy. The donor vector contains a 2A-RedStar-poly(A) expression cassette flanked by two arms
of 700 bp eGFP locus homology sequences. The anticipated HR product (HR_GRS) is shown below. Southern blot probes are shown as gray
boxes. The gray arrows represent primers used to confirm the 50 and 30 junctions generated by targeted integration of the respective reporter
construct. 2A, self-cleaving peptide sequence; RedStarnuc, variant of red fluorescent protein containing a nuclear membrane location signal;
eGFP, enhanced green fluorescence protein; CAG, cytomegalovirus early enhancer element coupled to chicken beta-actin promoter.
(B) Targeted knockin of RedStarnuc. ZFN-based HR resulted in 1.2% targeted eGFP
negRedStarpos hiPSCs at day 6 posttransfection as shown
by flow cytometry.
(C) Dose dependency of HR. A molar ratio of 1:10 (ZFN:donor) resulted in the most efficient HR as indicated by the proportion of
eGFPnegRedStarpos hiPSCs at day 7 posttransfection. The molar ratio 1:10 is equivalent to 1 mol of each ZFN plasmid to 10 mol of donor
plasmid, with a total amount of each ZFN plasmid of 10 mg (mean ± SEM of three independent experiments).
(D) Direct comparison of targeting efficiencies between two hCBiPS2eGFP reporter cell clones. Proportion of eGFPneg/RedStarpos cells on
day 6 after transfection with eGFP-ZFN plasmids and 2A-RedStar donor plasmid (mean ± SEM of three independent experiments using a
ZFN:donor ratio of 1:3).
(E) Fluorescence microscopy (day 6 after transfection) showing a group of targeted eGFPnegRedStarpos hiPSCs within a monolayer of cells,
which show the original eGFPposRedStarneg phenotype. Scale bars represent 100 mm.
(F) Tabular summaries of genomic analyses. PCR/Southern blot analyses of FACS-sorted eGFPnegRedStarpos single hiPSC clones isolated after
two targeting experiments (E1 and E2) applying different molecular ratios of ZFN:donor (for details, see Figures S2A and S2B).
(G) RedStar expression profile. Flow cytometry demonstrated comparable intensities of RedStar fluorescence in four different
eGFPnegRedStarpos iPSC clones.
See also Figure S2.
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robust, but 3-fold lower, eGFP gene-targeting efficiency as
compared with the hCBiPS2eGFPC7 cells (Figure 2D).
Successfully targeted hCBiPS2eGFPC7 cells expressed
bright RedStar protein targeted to the nuclear membrane
and completely lost their eGFP expression (Figure 2E).
Remarkably, microscopic analyses revealed various cell
clusters consisting of eGFPnegRedStarpos cells spread over
the plate, which may indicate a multitude of independent
HR events.
FACS was applied to sort and establish single-cell clones
from RedStarposeGFPneg hCBiPS2eGFPC7 cells for further
confirmation of HR-mediated gene targeting. PCR and
Southern blot analysis (Figures S2A and S2B) revealed
that almost all established clones were correctly targeted
(95%) and an unexpectedly high proportion of the clones
(36%–42%) did not carry additional nonhomologous
integrations (Figure 2F). All clones analyzed showed
comparable levels of RedStarnuc expression (Figure 2G).
Two representative RedStarposeGFPneg hCBiPS2eGFPC7
cell clones (E1_RSiPSC7 and E2_RSiPSC14) were chosen
for further characterization. Both clones retained a normal
karyotype (Figure S2C), suggesting the absence of delete-
rious side effects of the ZFN treatment. Morphologically,
both clones resembled hESCs and maintained their
RedStarnuc expression for up to 20 passages and during
differentiation (Figures S2D and S2E). Furthermore, they
expressed pluripotency markers such as OCT4, NANOG,
SOX2, SSEA-3, and SSEA-4, and could be differentiated
in vitro into derivatives of all three germ layers (Figures
S2D and S2E).
Efficient Gene Targeting of the Endogenous AAVS1
Locus in hPSCs using ZFNs and TALENs
Finally, we sought to evaluate gene targeting of an endoge-
nous locus and decided to use the human safe harbor site
AAVS1 for the generation of stable transgenic PSC lines.
Thus, AAVS1-specific ZFNs, together with one donor
plasmid for CAG-promoter-mediated ubiquitous expres-
sion of either eGFP or RedStarnuc (Figure 3A), were trans-
fected into two hiPSC lines and the hES3 cell line. The
targeting efficiency in terms of transgene (eGFP or
RedStarnuc) expressing cells was determined on day 14 after
transfection. Control transfections without ZFN plasmids
were performed to determine background expression due
to random integration and potential long-term transient
donor expression. Transfection of the respective donor
plasmid together with both AAVS1 ZFNs resulted on
average in 0.8% eGFPpos/RedStarpos hiPSCs/ESCs on day
14 after transfection when using a ratio of 1:3 (ZFN:donor).
In contrast, control transfection of the donor plasmid
alone resulted in an average of 0.08% eGFPpos/RedStarpos
cells, presumably representing cells with randomly inte-Stem Cegrated transgenes (Figure 3B). The observed targeting
efficiency was comparable to the results we obtained in
targeting the transgenic eGFP locus (see Figure 2) and was
verified by PCR analysis of targeted integration in the
AAVS1 locus for 97% of all established eGFPpos/RedStarpos
cell clones derived from two iPSC lines and one ESC line
(Figures 3C and S3A). Consistent with the results we ob-
tained in targeting the GFP reporter locus (see Figure 2F),
a very high proportion of AAVS1-targeted clones (25%–
79%) did not show any additional random integration of
the applied transgenes. Interestingly, 13%–75% of the
correctly targeted clones actually underwent HR at both
AAVS1 alleles (Figures 3C and S3A). Finally, two iPSC and
two ESC clones were characterized in more detail (data
for ESC clones not shown). The eGFP as well as the RedStar
transgenic clones retained a normal karyotype (Figure S3B)
and showed comparable bright fluorescence intensity
(Figure 3D). The expression of the respective transgene
was also stable in differentiating cells (Figure 3D) and was
observed in cell types of all three germ layers (Figures S3C
and S3D). In addition to the experiments with the ZFNs,
transfection experiments with AAVS1-specific TALENs
were performed with one hiPSC line. The targeting
efficiencies for TALENs were even higher than those for
ZFNs and resulted on average in 1.6% eGFPpos/RedStarpos
hiPSCs (Figure 3B).
Efficient Editing of the AAVS1 Locus in hiPSCs using
ssODNs
Targeting via designer nucleases typically uses donor
plasmids with homology arms of at least 200–800 bp.
Recent studies showed that short ssODNs can be used as
an alternative template for genome editing in human cells
(Chen et al., 2011; Ding et al., 2013; Soldner et al., 2011).
Importantly, such donor oligonucleotides would provide
a straightforward technique for footprintless gene editing
without the need for antibiotic or FACS selection, if
targeting could be achieved with similar efficiencies as
observed for conventional plasmid donors. We therefore
aimed to evaluate whether our efficient targeting protocol
would enable direct PCR screening for gene targeting
with ssODNs in the AAVS1 locus. As a donor, a 98 bp
ssODN carrying a HindIII site flanked by 43 bp of
homology on each side of the TALEN cut side was synthe-
sized (Figure 4A). The hCBiPS2 cell line was transfected
with AAVS1-specific TALENs together with the ssODN
and plated onto 96-well plates for limiting dilution. Up
to five cells survived per well, and PCR screening for
targeted integration showed successful insertion of the
ssODN in 32 out of 480 (7%) analyzed wells (Figure 4B).
Limiting dilution from nine positive wells to single-cell
clones yielded 33 clones from 144 (23%) with targeted
integration (Figure S4), from which we randomly chosell Reports j Vol. 2 j 107–118 j January 14, 2014 j ª2014 The Authors 111
Figure 3. Efficient Gene Targeting at the AAVS1 Locus in hiPSCs and hESCs
(A) Schematic illustration of the targeting strategy. Either a CAG-eGFP donor plasmid or a CAG-RedStarnuc donor plasmid carrying700 bp
of homology on both sides was applied. The gray arrows represent primers used to confirm the 50 and 30 junctions generated by targeted
integration of the respective reporter constructs. RedStarnuc, mutant of red fluorescent protein coupled to nuclear membrane location
signal; eGFP, enhanced green fluorescence protein; CAG, cytomegalovirus early enhancer element coupled to chicken b-actin promoter.
(B) Proportion of transgene (eGFP or RedStar) expressing cells on day 14 after transfection. ZFN- or TALEN-based donor integration
into the AAVS1 locus is shown in comparison with control transfection without nuclease plasmids (mean ± SEM of four independent
experiments).
(C) Summary of AAVS1 targeting and additional random donor integration in single-cell clones.
(D) Flow cytometry demonstrated comparable intensities of eGFP (left) or RedStar (right) fluorescence in three different hCBiPS2_AAVS1-
targeted cell clones, respectively (upper histograms). Notably, the biallelic targeted clones showed a slightly elevated transgene
expression compared with monoallelic targeted clones. In the lower histograms, the detected stable eGFP or RedStar expression of one
chosen transgenic clone is depicted on day 25 of EB-based differentiation (continuous line) as compared with nontargeted hCBiPS2 cells
(dashed line).
See also Figure S3.
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of their AAVS1 loci, HindIII digestion (Figure 4C), and
sequencing of the PCR products revealed correct monoal-
lelic HindIII conversion. Additional karyotype analysis
for three clones proved chromosomal integrity (data not
shown).112 Stem Cell Reports j Vol. 2 j 107–118 j January 14, 2014 j ª2014 The AutDISCUSSION
Genetic engineering techniques based on tailored nucle-
ases, such as ZFNs and TALENs, represent a genuine break-
through in gene targeting. In particular, these technologies
offer exciting opportunities for genetic engineering inhors
Figure 4. Efficient Editing of the AAVS1 Locus in hiPSCs Using an ssODN
(A) The schematic shows the 98 bp ssODN donor DNA designed to incorporate the HindIII site into the AAVS1 locus. The gray arrows
represent primers used to confirm the targeted integration and to amplify the PCR product for HindIII digestion.
(B) Schematic illustration of the targeting procedure and establishment of single-cell clones.
(C) PCR screening with two rounds of single-cell dilution identified 33 positive single iPSC clones (see Figure S4). Seven out of 33 clones
were randomly selected for further analyses. All seven clones carried a HindIII site introduced through targeted ssODN integration, as
demonstrated by HindIII site-specific PCR (upper picture) and HindIII digestion (lower picture). NC, negative control (hCBiPS2).
See also Figure S4.
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reporter genes as well as the correction and introduction
of disease-specific mutations. Apart from two studies
(Ding et al., 2013; Soldner et al., 2011), all known publica-
tions in this area have applied transgene-based antibiotic
selection to isolate targeted cell clones. Obviously, low
efficiencies typically continue to hamper the antibiotic-
selection-free isolation of correctly targeted clones and
impede footprintless correction and introduction of dis-
ease-specific mutations.
For the establishment and optimization of our targeting
protocol, we used a reporter iPSC line, which enabled us
to visualize successful ZFN-based gene targeting in hPSCs.
Using this line, we observed a proportion of up to 4% of
eGFPneg cells 6 days after transfection, which is similar to
what was recently reported for NHEJ-based dTomato re-
porter inactivation in the active DNMT3b locus in hESCs
by using CRISPR RNA-guided nucleases (Hou et al., 2013).Stem CeRemarkably, the observed proportion of eGFPneg cells
does not reflect the actual efficiency of DSB generation.
Targeted DSBs are probably induced in a considerably
higher proportion of cells, followed by an unknown fre-
quency of error-free repair by NHEJ. In order to extend
these findings to HR-based gene targeting, we constructed
a donor plasmid with two arms of700 bp of DNA homol-
ogous to the sequences enclosing the predicted ZFN
target site within the genomically inserted eGFP. Notably,
a red fluorescence reporter, RedStarnuc, which is targeted
to the nuclear membrane, was chosen in order to ensure
discrimination from potential autofluorescent cells.
Also of importance, the RedStarnuc was not coupled to a
promoter, but was cloned in frame to the eGFP sequence
via a 2A sequence to exclude transient, plasmid-based
RedStar expression, and to minimize a potential back-
ground due to undesired reporter expression after random
genomic insertion of the donor plasmid. Three days afterll Reports j Vol. 2 j 107–118 j January 14, 2014 j ª2014 The Authors 113
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ZFN plasmids and the donor plasmid, a population of up
to 1.2% of RedStarnuc
pos cells was detectable. At this time
point, the vast majority of these cells still expressed eGFP,
which can be explained by the typical persistence of
eGFP mRNA/protein in hPSCs for several days (Hartung
et al., 2013). Also, this persistence over a period of at least
3 days correlates perfectly with our observation of the
time course of fluorescence loss after NHEJ-based eGFP
inactivation. Six days after transfection, however, no
eGFPposRedStarpos cells were observed, indicating that
almost all RedStarpos cells represent correctly targeted cells.
The fact that cell clusters consisting of eGFPneg RedStarpos
cells were distributed over the whole plate speaks strongly
in favor of a multitude of independent HR events. In this
way, we achieved considerably higher targeting rates than
those previously reported for the correction of a mutant
eGFP reporter gene in 0.24% of hESCs and 0.14% of hiPSCs
(Zou et al., 2009).
Targeting experiments with a second eGFP reporter cell
line (hCBiPS2eGFPC16) showed similar results. The
observed 3-fold lower eGFP gene targeting efficiency for
hCBiPS2eGFPC16 as compared with hCBiPS2eGFPC7 cells
most likely represents clone-specific variations with respect
to survival rates after single-cell dissociation, transfection
efficiency, and general growth characteristics under
feeder-freemonolayer culture conditions. Correct targeting
in eGFPnegRedStarpos cells was confirmed through PCR and
Southern blot analysis in 39 out of 41 isolated clones
derived from two targeting experiments. In the two re-
maining clones, accurate targeting occurred with respect
to the 50 junction, but the 30 junction was not correctly
formed. As observed for the established eGFP reporter
clone, RedStar expression of different targeted clones was
almost uniform and persisted to a large extent during
differentiation.
Subsequently, we aimed to evaluate gene targeting for
another genomic locus. Through a highly efficient trans-
fection of AAVS1-specific ZFN and TALEN plasmids, we
obtained targeting efficiencies that were similar, or in the
case of TALENs even higher, than the 0.8% reported by
Lombardo et al. (2011) for eGFP integration in the same
locus using integrase-deficient lentiviral ZFN vectors. In
the case of plasmid-donor-based AAVS1 targeting, trans-
genic clones were identified based on the emergence of
eGFP or RedStar expression. Remarkably, only four nontar-
geted clones among a total of 120 isolated eGFPpos or
RedStarpos clones were detected by PCR. This high propor-
tion of 97% correctly targeted clones, together with the
fact that on average only 40% of correctly targeted clones
contained additional random integrations, underlines the
efficiency of ZFN-based gene targeting in our protocol.
Notably, the frequency of additional (nontargeted) integra-114 Stem Cell Reports j Vol. 2 j 107–118 j January 14, 2014 j ª2014 The Auttion was in a range similar to the 24%–38% reported in
previous studies that applies transgene-based antibiotic
selection after ZFN- or TALEN-mediated integration at
AAVS1 in hiPSCs (Hockemeyer et al., 2009, 2011; Zou
et al., 2009). Interestingly, compared with these studies,
which reported 6%–32% biallelic targeting (Hockemeyer
et al., 2009; Zou et al., 2011), we observed an even higher
proportion (13%–75%) of ZFN-targeted clones in which
both alleles had been edited correctly. Given that correct
targeting occurs only in up to 0.8% of transfected cells,
one would actually expect a much lower frequency of bial-
lelic targeting. The unexpectedly high proportion of bial-
lelic targeting events observed suggests that in themajority
of cells, the intracellular conditions do not allow for
efficient targeting, whereas the generation of DSBs and sub-
sequent repair through HR is highly efficient in only a rela-
tively small proportion of cells, resulting in a considerable
number of biallelic targeting events. These conditions may
include efficient transfection of the respective cell, the
appropriate timing of the peak of ZFN expression and
adequate cell-cycle phases (S or G2 phase for HR), and the
simultaneous expression of essential HR cofactors.
Finally, it is worth mentioning that our targeting proto-
col did not affect the pluripotent state of the resulting
clones, as indicated by the persistent expression of typical
pluripotency markers and efficient embryoid body (EB)-
based differentiation into derivatives of all three germ
layers. Moreover, we were able to exclude any karyotypic
abnormalities in our analyzed cell clones and also obtained
robust transgene expression from the AAVS1 locus upon
differentiation, indicating that ZFN/TALEN treatment and
application of a ROCK inhibitor (despite its potential side
effects; Chapman et al., 2010) did not affect or impair the
PSC properties.
Interestingly, we obtained similar targeting efficiencies
using TALENs in combination with short ssODNs with
2 3 43 bp of homology to the AAVS1 locus instead of
plasmid donors with 23 700 bp of homology. Here, we as-
sume that the lower pairing probability of a relatively short
homologous oligonucleotide sequence is compensated for
by the much higher number of molecules that enter the
transfected cells in comparisonwith a5.9 kbplasmiddonor.
The calculated high targeting frequency of 1.6% enabled
us to identify correctly targeted single-cell clones after
transfection and limiting dilution simply by PCR. To date,
the insertion of ssODNs on a clonal level has only been
reported by Soldner et al. (2011) and Ding et al. (2013),
who introduced point mutations in hESCs. However, in
contrast to our study, both of these groups preselected
positive transfected cells and subsequently established
clones with efficiencies of 0.4%–0.8% (Soldner et al.,
2011) and 1.5% (Ding et al., 2013) from the preselected
cell population.hors
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approach should be outlined. The targeted locus could be
considered as the most problematic, as the targeting effi-
ciency can widely vary among different genomic sites
depending on the chromatin state and local gene expres-
sion. Furthermore, transfection efficiencies may vary
among individual cell clones, and the required dissociation
steps may be critical depending on the culture characteris-
tics of the applied PSC clone. In case of low targeting
efficiencies and cell clones that are highly sensitive to
single-cell dissociation even in the presence of a ROCK
inhibitor, it may be easier and less time-consuming to
apply a targeting strategy based on antibiotic selection.
On the other hand, selection-free targeting has clear
advantages or is even crucial for various applications,
including seamless correction and the introduction of dis-
ease-specificmutations using ssODNs.When considering a
specific application of our approach, one should take into
account that the introduction of additional genetic ele-
ments may change characteristics of the targeted cell.
Even if the subsequent removal of such elements is possible
(e.g., through loxP or frt sites), such steps will also require
considerable additional efforts. It is important to perform
genetic engineering without the use of potentially immu-
nogenic reporter or selection genes if the engineered cells
are to be transplanted in animal studies or if a clinical appli-
cation is considered. The usefulness and the required work-
load of our approach therefore need to be weighed with
regard to the respective application.
In summary, we provide an efficient protocol for selec-
tion-independent gene targeting in hESCs and hiPSCs
usingZFNandTALENpairs specific for twodifferent targets.
The observed efficiencies enabled antibiotic-selection-free
isolation of targeted hPSC clones by FACS. Targeting of
the AAVS1 locus demonstrated robust CAG-promoter-
mediated transgene expression in undifferentiated PSCs
similar to that observed in their differentiated derivatives.
Finally, we show that TALEN/ssODN-based footprintless
gene editing in hiPSCs is actually feasible without any pre-
selection, and that correctly targeted clones can be isolated
simply via PCR.
The established targeting protocols will facilitate foot-
printless correction or introduction of disease-specific
mutations in patient-specific iPSCs for disease modeling,
drug screening, and ultimately the generation of clinically
useful transgenic iPSC derivatives.EXPERIMENTAL PROCEDURES
Cell Culture
We used hES-3 cells and hiPSC lines generated in our group by the
lentiviral transduction of cord-blood-derived endothelial cells
(hCBiPS2) (Haase et al., 2009) and cord-blood-derived CD34+ cellsStem Ce(HSC_F1441_4F_iPS2, termed hHSCiPS2) (Hartung et al., 2013).
Unless otherwise indicated, hiPSC lines and hES-3 cells were
cultured and expanded on irradiated mouse embryonic fibroblasts
(MEFs) in knockout Dulbecco’s modified Eagle’s medium supple-
mented with 20% knockout serum replacement, 1 mM L-gluta-
mine, 0.1 mM b-mercaptoethanol, 1% nonessential amino acid
stock (all from Life Technologies), and 10 ng/ml basic fibroblast
growth factor (bFGF; supplied by the Institute for Technical Chem-
istry, Leibniz University, Hannover, Germany) (Chen et al., 2012).
For generation of the eGFP reporter cell lines (hCBiPS2eGFPC7
and hCBiPS2eGFPC16), a CAG-promoter-driven eGFP expression
vector, together with a aMHCneo_PGKhygro selection vector,
was stably transfected into hCBiPS2 cells. Hygromycin-based clone
selectionwas initiated 72 hr posttransfection for 4 days. Upcoming
colonies were manually picked and transferred onto irradiated
feeder cells and expanded clonally.
Plasmid Vectors and Oligonucleotides
For this study, eGFP-specific ZFN (Ho¨her et al., 2012; Osiak et al.,
2011), AAVS1-specific ZFN (Hockemeyer et al., 2009), and
AAVS1-specific TALEN (Holkers et al., 2013) expression cassettes
were placed under control of a CAG promoter. The coding
sequences of the AAVS1-specific nucleases are indicated in the
Supplemental Experimental Procedures. In brief, all nucleases con-
tained an amino-terminal hemagglutinin tag and an SV40 nuclear
localization signal. The codon-optimized, AAVS1-specific zinc-
finger arrays were synthesized by GeneArt/Life Technologies and
fused to the obligate heterodimeric FokI variant EA-KV (Szczepek
et al., 2007) by the 4 AA linker LRGS (Ha¨ndel et al., 2009). TALENs
are based on the ND134/C+17 architecture (Mussolino et al., 2011)
and contain wild-type FokI nuclease domains. For generation of
the eGFP donor plasmid, a 2A protease sequence (Szymczak and
Vignali, 2005) was fused in frame at the beginning of an improved
version of the red fluorescent protein coupled to a nuclear mem-
brane location signal (RedStarnuc) (Gruh et al., 2005; Okita et al.,
2004). Afterward, the resulting 2A-RedStar-poly(A) expression
cassette was cloned between two arms of 700 bp eGFP locus
homology sequences in a pJet1.2 (Thermo Scientific) expression
vector backbone. For generation of the AAVS1 donor plasmids,
CAG-eGFP and CAG-RedStarnuc expression cassettes were cloned
between two arms of 700 bp AAVS1 locus homology sequences
in a pUC19 expression vector backbone (Life Technologies). All
oligonucleotides, including PCR primers (Table S1), weremanufac-
tured by Eurofins MWGOperon and dissolved in water at 100 mM.
Transfection, Flow Cytometry, and Clone
Establishment
In the optimization experiments and for eGFP targeting, cells were
detached from the feeder layer by 0.2% collagenase IV (Life
Technologies) followed by an incubation step with TrypLE (Life
Technologies) for single-cell dissociation. In all other experiments,
cells were expanded as monolayer cultures on Geltrex (Life
Technologies) for at least two passages as previously described
(Burridge et al., 2011) and harvested by Accutase (PAA).
Transfections using the Amaxa Nucleofection system were
performed according to the manufacturer’s protocol. The majority
of transfections, however, were performed using the Neonll Reports j Vol. 2 j 107–118 j January 14, 2014 j ª2014 The Authors 115
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ated cells were resuspended in 100 ml NEON buffer with various
amounts of ZFN/TALEN and donor plasmids or ssODN (eGFP
targeting, e.g., 1:3 = 10 mg of each ZFN plasmid + 30 mg donor
plasmid; AAVS1 targeting: 5 mg of each ZFN/TALEN plasmid +
15 mg donor plasmid), electroporated with two pulses at 1,000 V
for 20 ms, and plated onto Geltrex-coated dishes with MEF
conditioned medium (CM) supplemented with 10 mM ROCK
inhibitor Y-27632 (RI).
Transfected cells were cultivated as a monolayer prior to flow-
cytometric analysis using the FACSCalibur cell analyzer (BD Biosci-
ence) and FlowJo 7.6.5 software (Celeza). For clone generation,
cells were harvested from the monolayer culture by either TrypLE
or Accutase on day 7 (for eGFP targeting) or day 12 (for AAVS1
targeting) after transfection, and were sorted on the FACSAria IIu
(BD Bioscience) or XDP (Beckman-Coulter) for eGFPpos or RedStar-
pos cells. Sorted populations were plated onto Geltrex-coated
dishes. Arising colonies were picked manually and transferred
into feeder-based culture conditions. For gene editing using
ssODNs, 13 106 hiPSCs were resuspended in 100 ml NEON buffer,
electroporated with 5 mg of each TALEN-encoding plasmid and 5 ml
of the ssODN (50-GTTCTGGGTACTTTTATCTGTCCCCTCC ACCC
CACAGTGGGGCCCCAAGCTTGGGCACTAGGGACAGGATTGGT
GACAGAAAAGCCCCATCCTTAGGC-30), and plated onto Geltrex-
coated dishes with CM+RI. On day 3 after transfection, 10 cells
per well were seeded intoGeltrex-coated 96-well plates. On average,
one to five single cells survived per well and were analyzed via
direct PCR screening. Subsequent subcloning via limiting dilution
(20 cells/cm2) resulted in single-cell clones, which were also
analyzed via PCR screening (see schematic illustration in Figure 4B).PCR Screening and Characterization of Transgenic
Clones
Total RNAwas preparedwith the RNeasy Kit (Macherey-Nagel) and
reverse transcribed with Superscript II (Life Technologies) using
random primers according to the manufacturer’s instructions.
Genomic DNA was prepared using the QIAamp DNA Blood Mini
Kit (QIAGEN) according to the manufacturer’s instructions, and
1 ml of cDNA or 100 ng of gDNAwas amplified by PCR with GoTaq
DNA polymerase (Promega). Sequences and specifications of the
primers are shown in Table S1. For gene editing using ssODNs,
cell lysis was done in 96-well plates using directPCR Lysis Reagent
(PeqLab). Subsequently, 2 ml of the lysate was directly applied for
PCR reaction.
For Southern blot analysis, 10 mg of genomic DNA was digested
as indicated with EcoRI, ScaI, BglII, or BsmI. Fragments were sepa-
rated on a 0.8% TAE-agarose gel, transferred onto Biodyne B nylon
membrane (PALL Life Sciences), hybridized with radioactive
labeled DNA fragments using the DecaLabel DNA Labeling Kit
(Fermentas), and stripped using standard procedures (Stocking
et al., 1988). The hybridization probe for the copy number of
genomic eGFP integrations in the hCBiPS2eGFP reporter cell lines
was an EcoRI/BglII fragment of eGFP. For determination of
targeted and additional donor integrations, the probes were as
follows: a PstI fragment (792 bp) of pJet_2A-RedStar-poly(A)
(30 probe) and a AvrII/MfeI fragment (570 bp) of pJet_2A-RedStar-
poly(A) (50 probe).116 Stem Cell Reports j Vol. 2 j 107–118 j January 14, 2014 j ª2014 The AutImmunocytological Staining
Cells were fixed with 4% paraformaldehyde (w/v) and stained by
standard protocols using primary antibodies, as listed in Table
S2, and appropriate secondary antibodies (DyLight 488_
donkey_anti-mouse_IgG and IgM, DyLight 488_donkey_anti-
goat_IgG, DyLight 594_donkey_anti-mouse_IgG; 1:200; Jackson
ImmunoResearch Laboratories). The corresponding isotype anti-
bodies were used for negative control staining. Cells were counter-
stained with DAPI (Sigma) and analyzed with an AxioObserver A1
fluorescence microscope and Axiovision software 4.71 (Zeiss).In Vitro Differentiation of hPSCs
hPSCs were detached from the feeder layer by collagenase IV,
dispersed into small clumps, and cultured in differentiation
medium (80% Iscove’s modified Dulbecco’s medium supple-
mented with 20% fetal calf serum, 1 mM L-glutamine, 0.1 mM
b-mercaptoethanol, and 1% nonessential amino acid stock) in
ultralow-attachment plates (Corning) for 7 days. Subsequently,
EBs were plated onto 0.1% gelatin-coated tissue culture
dishes and cultured for a further 13 days before fixation and
immunostaining.Karyotype Analysis
After trypsination, metaphases were prepared according to stan-
dard procedures. Fluorescence R-banding using chromomycin A3
and methyl green was performed as previously described in detail
(Schlegelberger et al., 1999). At least 15 metaphases were analyzed
per clone. Karyotypes were described according to the Interna-
tional System for Human Cytogenetic Nomenclature (ISCN).Statistical Analysis
Results are reported as mean ± SEM. Statistical analyses were per-
formed with GraphPadPrism5. The significance of two groups
was analyzed using the unpaired t test (*p < 0.05; **p < 0.005;
***p < 0.0005).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and two tables and can be found with this
article online at http://dx.doi.org/10.1016/j.stemcr.2013.12.003.
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